Table 3.

Main studies showing the clinical impact of Pseudomonas aeruginosa on people with bronchiectasis.

Authors Date	Study Design	Site/Year of Study	Mean Age in Years	People Included	% of Colonization by P. aeruginosa	Years of Follow-Up	Results
Hernandez 2002 [143]	Prospective Cohort	Spain 1999–2000	56	70	20	Transversal	QoL, FEV1, FVC
Martinez-García 2007 [132]	Prospective	Spain 2003	69.9	76	19.7	2 years	FEV1 loss
Loebinger 2009 [138]	Longitudinal	UK 1994–2009	51.7	91	22	13	Mortality
Chalmers 2014 [144]	Prospective Cohort	UK					Pulmonary exacerbations, FEV1, FVC, QoL, radiographical severity, hospitalizations, mortality
		2008–12	67	608	11.5	4
		2011–14	68	289	14	3
Martinez-García 2014 [131]	Retrospective Multi-center	Spain Prior to 2005	58.7	819	31.8	5	Mortality
Goeminne 2014 [145]	Prospective Cohort	Belgium 2006–12	68	253	7.9	5.18	Pulmonary exacerbations, FEV1, FVC, radiographical severity, hospitalizations, mortality
Mc Donnell 2015 [146]	Retrospective	UK 2007–9	63	212	16	5	Pulmonary exacerbations, hospitalization, FEV1, FVC, radiographical severity, mortality
Finch 2015 [4]	Systematic review of 21 studies	Italy, UK, Belgium, Spain, Australia, Ireland, China 1990–2014	51.7–68	3683	21.4	Transversal 13 years	Pulmonary exacerbations, FEV1, FVC, QoL, radiographical severity, hospitalization, mortality
Aliberti 2016 [147]	Prospective Cohort	5 European countries	60	1145	16	3	Clusters, pulmonary exacerbations, QoL, mortality
De La Rosa 2018 [148]	Retrospective Multi-center	Spain	67	456	37.2		Costs
Araujo 2017 [149]	Prospective Multi-center	Europe Israel	67	2596	15	5	Mortality Pulmonary exacerbations QoL
Martínez-Garcia 2020 [133]	Prospective RIBRON	Spain	69.1	849	25.7	1–4	FEV1 loss

FEV1: forced expiratory volume in first second; FVC: forced vital capacity; QoL: quality of life.